EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

2024 Update in Heart Failure

Alberto Beghini, Antonio Maria Sammartino, Zoltán Papp, Stephan von Haehling, Jan Biegus, Piotr Ponikowski, Marianna Adamo, Luigi Falco, Carlo Mario Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra und 1 weitere

ESC Heart Failure · 01.02.2025 · 12 (1) · 8-42

DOI: 10.1002/ehf2.14857 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 28.05.2024. Verfasst von Alberto Beghini und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Un…. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Disease Management, Practice Guidelines as Topic. Die Arbeit wurde bisher 216-mal zitiert (Crossref) und nennt 406 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of the 2021 HF guidelines introduced new key recommendations based on the results of the last years of science. First, two drugs, sodium–glucose co-transporter-2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for the prevention of HF in patients with diabetic chronic kidney disease (CKD). Second, SGLT2 inhibitors are now recommended for the treatment of HF across the entire left ventricular ejection fraction spectrum. The benefits of quadruple therapy in patients with HF with reduced ejection fraction (HFrEF) are well established. Its rapid and early up-titration along with a close follow-up with frequent clinical and laboratory re-assessment after an episode of acute HF (the so-called ‘high-intensity care’ strategy) was associated with better outcomes in the STRONG-HF trial. Patients experiencing an episode of worsening HF might require a fifth drug, vericiguat. In the STEP-HFpEF-DM and STEP-HFpEF trials, semaglutide 2.4 mg once weekly administered for 1 year decreased body weight and significantly improved quality of life and the 6 min walk distance in obese patients with HF with preserved ejection fraction (HFpEF) with or without a history of diabetes. Further data on safety and efficacy, including also hard endpoints, are needed to support the addition of acetazolamide or hydrochlorothiazide to a standard diuretic regimen in patients hospitalized due to acute HF. In the meantime, PUSH-AHF supported the use of natriuresis-guided diuretic therapy. Further options and most recent evidence for the treatment of HF, including specific drugs for cardiomyopathies (i.e., mavacamten in hypertrophic cardiomyopathy and tafamidis in transthyretin cardiac amyloidosis), device therapies, cardiac contractility modulation and percutaneous treatment of valvulopathies, with the recent finding from the TRILUMINATE Pivotal trial, are also reviewed in this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeDisease ManagementPractice Guidelines as TopicHumansSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Stichwörter der Autor:innen

SGLT2 inhibitorscomorbiditiesfinerenoneheart failurepreventionprognosistreatment

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany.
  • German Centre for Cardiovascular Research (DZHK), partner site Göttingen, Göttingen, Germany.
  • Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland.
  • Heart Failure Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital Naples, Naples, Italy.

Zitieren

APA

Beghini, A., Sammartino, A. M., Papp, Z., von Haehling, S., Biegus, J., Ponikowski, P., Adamo, M., Falco, L., Lombardi, C. M., Pagnesi, M., Savarese, G., Metra, M., & Tomasoni, D. (2025). 2024 Update in Heart Failure. ESC Heart Failure, 12(1), 8-42. https://doi.org/10.1002/ehf2.14857

Vancouver

Beghini A, Sammartino AM, Papp Z, von Haehling S, Biegus J, Ponikowski P, et al. 2024 Update in Heart Failure. ESC Heart Failure. 2025;12(1):8-42. doi:10.1002/ehf2.14857

BibTeX
@article{Beghini2025,
  author = {Beghini, Alberto and Sammartino, Antonio Maria and Papp, Zoltán and von Haehling, Stephan and Biegus, Jan and Ponikowski, Piotr and Adamo, Marianna and Falco, Luigi and Lombardi, Carlo Mario and Pagnesi, Matteo and Savarese, Gianluigi and Metra, Marco and Tomasoni, Daniela},
  title = {2024 Update in Heart Failure},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {1},
  pages = {8--42},
  doi = {10.1002/ehf2.14857}
}
Kostenlos starten →